...
首页> 外文期刊>ACS Omega >Photochemical and Photobiological Properties of Pyridyl-pyrazol(in)e-Based Ruthenium(II) Complexes with Sub-micromolar Cytotoxicity for Phototherapy
【24h】

Photochemical and Photobiological Properties of Pyridyl-pyrazol(in)e-Based Ruthenium(II) Complexes with Sub-micromolar Cytotoxicity for Phototherapy

机译:吡啶基 - 吡唑(IN)氟乙醇(II)络合物与亚微摩尔细胞毒性的光化学和光生物学性质进行光疗法

获取原文
           

摘要

The discovery of new light-triggered prodrugs based on ruthenium (II) complexes is a promising approach for photoactivated chemotherapy (PACT). The light-mediated activation of “strained” Ru(II) polypyridyl complexes resulted in ligand release and produced a ligand-deficient metal center capable of forming covalent adducts with biomolecules such as DNA. Based on the strategy of exploiting structural distortion to activate photochemistry, biologically active small molecules were coordinated to a Ru(II) scaffold to create light-triggered dual-action agents. Thirteen new Ru(II) complexes with pyridyl-pyrazol(in)e ligands were synthesized, and their photochemical reactivity and anticancer properties were investigated. Isomeric bidentate ligands were investigated, where “regular” ligands (where the coordinated nitrogens in the heterocycles are linked by C–C atoms) were compared to “inverse” isomers (where the coordinated nitrogens in the heterocycles are linked by C–N atoms). Coordination of the regular 3-(pyrid-2-yl)-pyrazol(in)es to a Ru(II) bis-dimethylphenanthroline scaffold yielded photoresponsive compounds with promising photochemical and biological properties, in contrast to the inverse 1-(pyrid-2-yl)-pyrazolines. The introduction of a phenyl ring to the 1N -pyrazoline cycle increased the distortion in complexes and improved ligand release upon light irradiation (470 nm) up to 5-fold in aqueous media. Compounds 1 –8 , containing pyridyl-pyrazol(in)e ligands, were at least 20–80-fold more potent than the parent pyridyl-pyrazol(in)es, and exhibited biological activity in the dark, with half-maximal inhibitory concentration (IC_(50)) values ranging from 0.2 to 7.6 μM in the HL60 cell line, with complete growth inhibition upon light irradiation. The diversification of coligands and introduction of a carboxylic acid into the Ru(II) complex resulted in compounds 9 –12 , with up to 146-fold improved phototoxicity indices compared with complexes 1 –8 .
机译:基于钌(II)复合物的新光触发前药的发现是一种有希望的光活化化疗(PATC)的方法。 “应变”Ru(II)聚吡啶络合物的光介导的活化导致配体释放,并制备了能够形成具有生物分子如DNA的共价加合物的配体缺陷金属中心。基于利用结构变形的策略激活光化学,对生物活性的小分子与Ru(II)支架配位,以产生光触发的双作用剂。合成了用吡啶基 - 吡唑(IN)E配体的十三枚新Ru(II)配合物,研究了它们的光化学反应性和抗癌性能。研究了异构双齿配体,其中“常规”配体(其中杂环中的配位氮通过C-C原子连接)与“逆”异构体(其中杂环中的配位氮通过C-N原子连接) 。与逆1-(Pyrid-2相反 - - 吡唑啉。将苯环的引入1 N-戊唑啉循环增加了复合物中的变形,并改善了在光照(470nm)上高达5倍的含水介质的配体释放。含有吡啶基 - 吡唑(In)配体的化合物 1 - 8比亲本吡啶基 - 吡唑(in)ES更有效地为至少20-80倍,并在黑暗中表现出生物活性,具有半最大抑制浓度(IC_(50))值在HL60细胞系中的0.2至7.6μm的值,在光照射时具有完全的生长抑制。 Cooligands的多样化和将羧酸引入Ru(II)复合物中,得到化合物 9 - 12,与复合物 1 - 相比,高达146倍的改善的光烧蚀指数8。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号